TP53 and acute myeloid leukemia: While the eprenetapopt in combination with AZA + VEN is tolerable, whether or not the triplet regimen represents an improvement over AZA + VEN (CR/CRi rate of 55.3%; median OS ~ 5–7 months in TP53-mutated AML) [4,62] will require randomized investigations.